Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5764227 versus topotecan in relapsed small cell lung cancer
2025-521627-78-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Jan 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing GSK5764227 with Topotecan (2 arms). Primary endpoint: Overall survival. Planned start Jan 2026; status: authorised.
02
Drugs
risvutatug rezetecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-521627-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521627-78-00.